Complete resection of recurrent and initially unresectable dermatofibrosarcoma protuberans downsized by Imatinib

World Journal of Surgical Oncology

JA van der Hage¹  Hester H van Boven⁵  Rick LM Haas⁴  J Martijn Kerst²  Martine A van Huizum³  Houke M Klomp¹  Frits van Coevorden¹  Dennis A Wicherts¹ 

[1] Department of Surgical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands;Department of Medical Oncology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands;Department of Plastic and Reconstructive Surgery, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands;Department of Radiotherapy, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands;Department of Pathology, Netherlands Cancer Institute - Antoni van Leeuwenhoek Hospital, Plesmanlaan 121, Amsterdam, 1066CX, the Netherlands

关键词: Surgery;    Imatinib;    Dermatofibrosarcoma protuberans;   

Others  :  825979
DOI  :  10.1186/1477-7819-11-59

 received in 2012-07-02, accepted in 2013-02-15,  发布年份 2013

【 摘 要 】

Curative surgical treatment of recurrent, locally advanced dermatofibrosarcoma protuberans is often limited owing to a close relation of the tumor with important anatomical structures. Targeted therapy with imatinib, a tyrosine kinase inhibitor, may cause significant reduction of tumor volume, thereby enabling radical surgery. This treatment strategy, therefore, offers a chance of cure for selected patients with advanced dermatofibrosarcoma protuberans. In addition, preoperative treatment with imatinib may decrease possible disfigurement related to radical surgery for large tumors.

【 授权许可】

   
2013 Wicherts et al; licensee BioMed Central Ltd.

【 图 表 】

Figure 1.

Figure 2.

【 参考文献 】

• [1]Rutkowski P, Wozniak A, Switaj T: Advances in molecular characterization and targeted therapy in dermatofibrosarcoma protuberans. Sarcoma 2011, 2011:959132.
• [2]Kransdorf MJ: Malignant soft-tissue tumors in a large referral population: distribution of diagnoses by age, sex, and location. AJR Am J Roentgenol 1995, 164:129-134.
• [3]Criscione VD, Weinstock MA: Descriptive epidemiology of dermatofibrosarcoma protuberans in the United States, 1973 to 2002. J Am Acad Dermatol 2007, 56:968-973.
• [4]Chang CK, Jacobs IA, Salti GI: Outcomes of surgery for dermatofibrosarcoma protuberans. Eur J Surg Oncol 2004, 30:341-345.
• [5]Kimmel Z, Ratner D, Kim JYS, Wayne JD, Rademaker AW, Alam M: Peripheral excision margins for dermatofibrosarcoma protuberans: a meta-analysis of spatial data. Ann Surg Oncol 2007, 14:2113-2120.
• [6]Rutgers EJ, Kroon BB, Albus-Lutter CE, Gortzak E: Dermatofibrosarcoma protuberans: treatment and prognosis. Eur J Surg Oncol 1992, 18:241-248.
• [7]Haas RL, Keus RB, Loftus BM, Rutgers EJ, van Coevorden F, Bartelink H: The role of radiotherapy in the local management of dermatofibrosarcoma protuberans. Soft Tissue Tumours Working Group. Eur J Cancer 1997, 33:1055-1060.
• [8]Rubin BP, Schuetze SM, Eary JF, Norwood TH, Mirza S, Conrad EU, Bruckner JD: Molecular targeting of platelet-derived growth factor B by imatinib mesylate in a patient with metastatic dermatofibrosarcoma protuberans. J Clin Oncol 2002, 20:3586-3591.
• [9]Labropoulos SV, Fletcher JA, Oliveira AM, Papadopoulos S, Razis ED: Sustained complete remission of metastatic dermatofibrosarcoma protuberans with imatinib mesylate. Anticancer Drugs 2005, 16:461-466.
• [10]McArthur GA, Demetri GD, van Oosterom A, Heinrich MC, Debiec-Rychter M, Corless CL, Nikolova Z, Dimitrijevic S, Fletcher JA: Molecular and clinical analysis of locally advanced dermatofibrosarcoma protuberans treated with imatinib: imatinib target exploration consortium study B2225. J Clin Oncol 2005, 23:866-873.
• [11]Abbott JJ, Erickson-Johnson M, Wang X, Nascimento AG, Oliveira AM: Gains of COL1A1- PDGFB genomic copies occur in fibrosarcomatous transformation of dermatofibrosarcoma protuberans. Mod Pathol 2006, 19:1512-1518.
• [12]Llombart B, Monteagudo C, Sanmartín O, López-Guerrero JA, Serra-Guillén C, Poveda A, Jorda E, Fernandez-Serra A, Pellín A, Guillén C, Llombart-Bosch A: Dermatofibrosarcoma protuberans: a clinicopathological, immunohistochemical, genetic (COL1A1-PDGFB), and therapeutic study of low-grade versus high-grade (fibrosarcomatous) tumors. J Am Acad Dermatol 2011, 65:564-575.